Seòmar agus comataidhean

Health boards can take a range of actions in response to any breach of terms by a pharmacy contractor. Community pharmacy contractors are required to meet the Terms of Service as set out in Schedule 1 of the National Health Service (Pharmaceutical Services) (Scotland) Regulation 2009. Should, in the opinion of the Health Board, a community pharmacy contractor breach the Terms of Service, they can consider taking any appropriate action in line with the noted Regulation and the National Health Service (Discipline Committees) (Scotland) Regulations 2006.

The General Pharmaceutical Council (GPhC) is the UK's independent regulator for pharmacists, pharmacy technicians and pharmacy premises and ensures pharmacy services are delivered in accordance with the required standards. There are no plans to instruct the Care Inspectorate to regulate this sector.

The Scottish Government has no immediate plans to amend the current National Health Service ((Pharmaceutical Services) (Scotland) Regulations 2009. The Scottish Government is committed to review the current contractual arrangements in line with the recommendations set out in the Achieving Excellence in Pharmaceutical Care strategy.

I announced on 4 October that the Scottish Government would be devolving powers to NHS Boards to utilise local flexibilities within NHS Pension arrangements, and offer ‘pension recycling’. This means NHS Boards will have the ability to assist staff affected by annual and lifetime allowance pension taxation issues. This action is intended to support the retention of staff and support service delivery as we approach winter.

Wider issues relating to pensions are a reserved matter and the power to fully resolve deficiencies with the current system are a matter for the UK Government.

All NHS Scotland Boards are providing assessment and support for people with long COVID, delivered across the full range of services provided by our NHS.

In 2022-23, funding of £18 billion is provided for the health portfolio. This substantial investment is already benefitting a range of services that are supporting the needs of people living with long COVID.

In addition, we have established a £10 million ‘Long COVID Support Fund’ and are investing an initial £3 million from the fund over this financial year to enable NHS Boards to continue to develop and deliver the best models of care for their local populations.

For 2022-23, the funding allocations to thirteen of the fourteen territorial Health Boards (NHS Orkney did not request funding), I refer the member to the answer to question S6W-09934 on 23 August 2022. All answers to written Parliamentary Questions are available on the Parliament’s website, the search facility for which can be found at: https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

£10 million of funding was announced for long COVID in 2021 for a 3 year period, with the first year’s expenditure being £3 million. We will monitor the progress of the initiatives being funded by this investment and use this to inform expenditure in the remaining 2 years to best meet the needs of people living with long COVID.

In 2022-23, funding of £18 billion is provided for the health portfolio. This substantial investment is already benefitting a range of services that are supporting the needs of people living with long COVID.

Around the world, science has begun the work of trying to find an explanation, and treatments, for long COVID. We are investing £2.5 million in 9 Scottish-led research studies through our Chief Scientist Office. These studies aim to improve the understanding of the long-term effects of COVID-19 on physical and mental health and wellbeing in Scotland, and inform clinical interventions to support recovery and rehabilitation.

I refer the member to the answer to question S6W-10043 on 24 August 2022. All answers to written Parliamentary Questions are available on the Parliament’s website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

Any large infrastructure organisation that provides an essential service requires significant access to cash to maintain its activities and to respond to unforeseen events. Scottish Water’s cash balances each year are largely a function of when the business borrows from the Scottish Government relative to when capital investments are made; unlike similar infrastructure businesses, Scottish Water does not have access to any other credit facilities. Some of that capital investment will be on projects not delivered in the preceding regulatory period. Furthermore, at any point in time Scottish Water has on-going investment projects and hence has contractual commitments with its delivery partners and it must ensure it has sufficient funds to meet those contractual commitments. At 31 March 2022 Scottish Water had contractual capital commitments of £455.6m and at 31 March 2021 this figure was £541.4m, hence my comments in the Scottish Parliament on 18 May 2022 that Scottish Water's cash balance is ''substantially allocated at any time to investment projects''.

Ministers’ charging policies and Objectives for the water industry are clearly set out in the key framework documents that can be found on the Scottish Government’s website. Current circumstances facing the industry, indeed the country at large, are undoubtedly challenging and the Scottish Government will maintain regular dialogue with Scottish Water to support the continued delivery of all of Ministers’ Objectives over the current regulatory period. The affordability of charges is a matter for Scottish Water’s Board to consider alongside the requirement to meet its other statutory obligations. WICS has no powers to require a particular outcome in the charge setting process beyond setting the charge caps which are established to protect customers.

NHS Scotland and the Scottish Government remains focused on delivering high-quality care in the safest possible way for patients of all cancer types, including blood cancers.

The National Cancer Plan, published on 9 December 2020, includes actions to improve access to treatments for all cancers.

The Covid-19 National Cancer Medicines Advisory Group (NCMAG) was established to oversee interim governance arrangements for cancer medicines in response to the impact of Covid-19 on the health service. These arrangements include two new medicines approved for use with patients with leukaemia, a type of blood cancer.

We have established the Scottish Cancer Network, which is a dedicated national resource to support and facilitate a ‘Once for Scotland’ approach to cancer services. Its aim is to enable equitable access to care and treatment across Scotland.

Lastly, an updated Framework for Effective Cancer Management was published on 3 December 2021. It supports clinicians and NHS managers to drive improvements in cancer pathways, including blood cancers, providing Health Boards with the tools to effectively manage cancer patients and ultimately recover waiting times.